在心力衰竭中描述维里西瓜特治疗:在中国的一项多中心真实世界研究
Qi Wang1, Guangchuan Wang2, Jiecheng Peng3
1Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230001 Hefei, Anhui, China.
Reviews in cardiovascular medicine
|January 1, 2025
概括
维里西瓜特在现实临床环境中被用于更广泛的心力衰竭 (HF) 患者群体,而不是以前研究的. 这项研究发现,只有44.9%的患者符合VICTORIA试验标准,这表明医生应用范围更广.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 有限的现实世界数据存在于 vericiguat.at 的临床益处.
- 这项研究旨在在常规临床实践中评估输送的特征和作用.
研究的目的:
- 在现实世界心力衰竭 (HF) 环境中评估 vericiguat 的临床特征和治疗效果.
- 为了与VICTORIA试验中的患者进行对照,将接受 vericiguat的患者的基线特征与VICTORIA试验中的患者进行比较.
主要方法:
- 从2022年9月到2023年8月,在9家医院进行了285名HF患者的回顾性收集和前性随访.
- 评估12个月后N终端亲B型性尿素 (NT-proBNP) 的变化.
- 患者人口统计和临床状况与VICTORIA试验纳入标准的比较.
主要成果:
- 该研究包括285名患者,平均年龄为64.8岁;94.7%是NYHAIII-IV类,66.4%的射出分数减少.
- 78.2%的患者在住院期间开始服用维里西瓜特,其中37.1%接受了四重抗高频疗法.
- 只有44.9%的患者符合VICTORIA试验的纳入标准.
结论:
- 医生在现实实践中在更广泛的心力衰竭患者中利用 vericiguat,而不是在VICTORIA试验中使用的患者.
- 这表明 vericiguat的应用正在扩展到严格定义的试验人群之外.
相关概念视频
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...